Related Experiment Video
Updated: Jun 4, 2026
09:29
Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
Targeted biotherapy in metastatic colorectal carcinoma: Current practice
W Cacheux1, C Le Tourneau, B Baranger
1Département d'oncologie médicale, institut Curie, 25, rue d'Ulm, 75248 Paris cedex 05, France. wulfran.cacheux@curie.net
Journal of Visceral Surgery
|February 1, 2011
Summary
Targeted therapy improves survival in metastatic colorectal cancer (mCRC) by blocking VEGF and EGFR. KRAS mutations predict poor response to EGFR inhibitors, guiding treatment decisions for mCRC patients.
Area of Science:
- Oncology
- Medical Genetics
Background:
- Targeted therapy is crucial for managing metastatic colorectal cancer (mCRC).
- Monoclonal antibodies targeting vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) improve median overall survival beyond 24 months when combined with chemotherapy.
Purpose of the Study:
- To review the current landscape of targeted therapies in mCRC.
- To identify predictive factors for treatment efficacy and discuss limitations.
Main Methods:
- Review of current literature on targeted therapies in mCRC.
- Analysis of the role of VEGF and EGFR inhibitors.
- Examination of predictive markers such as KRAS mutations.
Main Results:
- Bevacizumab (VEGF inhibitor) efficacy lacks predictive markers.
- KRAS mutations predict non-response or adverse response to EGFR inhibitors, restricting their use to wild-type KRAS tumors.
- Combined targeted therapy has not demonstrated additional benefit.
- Treatment toxicity is moderate and not cumulative with chemotherapy.
Conclusions:
- KRAS mutation status is a key determinant for EGFR-targeted therapy in mCRC.
- Further research is needed to establish optimal biotherapies and treatment strategies for mCRC.
- While VEGF and EGFR inhibitors offer survival benefits, predictive markers and combination strategies require further investigation.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...